Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 3.28% is 27% below its 5-year average of 4.50%, near the low end of its 5-year range (0.00%–17.05%).
As of the fiscal period ended Tuesday, June 30, 2026. 54.31% below its 12-month average of 7.17%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.28%.
DEBT TO ASSETS RATIO
3.28%
DEBT TO ASSETS RATIO AVG TTM
7.17%
DEBT TO ASSETS RATIO AVG 3Y
7.25%
DEBT TO ASSETS RATIO AVG 5Y
4.50%
DEBT TO ASSETS RATIO AVG 10Y
0.31%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-54.31%
CURRENT VS 3Y AVG
-54.79%
CURRENT VS 5Y AVG
-27.11%
CURRENT VS 10Y AVG
+945.26%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 732 covered companies
CURRENT VS SECTOR MEDIAN
+3176.76%
vs the sector median at left
Definium Therapeutics, Inc.
Market Cap
$4.72B
Debt to Assets Ratio
3.28%
TTM Avg
7.17%
3Y Avg
7.25%
5Y Avg
4.50%
Market Cap
$4.69B
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.65B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.85B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.86B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.90B
Debt to Assets Ratio
0.73%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.43B
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.42B
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.72B | 3.28% | 7.17% | 7.25% | 4.50% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 0.09% | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 0.38% | N/A | N/A | N/A |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.85B | 0.00% | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.59B | 0.20% | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.86B | 0.00% | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.90B | 0.73% | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.43B | 0.41% | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.42B | 0.64% | N/A | N/A | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.37B | 0.01% | N/A | N/A | N/A |
Debt/Assets
3.3%
Debt/Equity
0.04
Current Ratio
6.95
Interest Coverage
-30.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 3.28% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 17.05% |
| 2025-06-30 | 15.54% |
| 2025-03-31 | 8.00% |
| 2024-12-31 | 7.23% |
| 2024-09-30 | 7.60% |
| 2024-06-30 | 9.04% |
| 2024-03-31 | 5.15% |
| 2023-12-31 | 11.34% |
| 2023-09-30 | 9.94% |
| 2023-06-30 | 0.05% |
| 2023-03-31 | 0.05% |
| 2022-12-31 | 0.04% |
| 2022-09-30 | 0.04% |
| 2022-06-30 | 0.05% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-08-31 | 0.00% |
| 2019-05-31 | 0.00% |
| 2019-02-28 | 0.00% |
| 2018-11-30 | 0.00% |
| 2018-08-31 | 0.00% |
| 2018-05-31 | 0.00% |
| 2018-02-28 | 0.35% |
| 2017-11-30 | 0.00% |
| 2017-08-31 | 0.39% |
| 2017-05-31 | 0.00% |
| 2017-02-28 | 0.00% |
| 2016-11-30 | 0.00% |
